Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Strengthening focus in Alzheimer's disease and neuroscience pipeline
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
Subscribe To Our Newsletter & Stay Updated
